NCT03229083

Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma

Monitoring of Treatment Related Toxicities from Oral Targeted Agents and Immunotherapy Among Patients with Advanced Renal Cell Carcinoma (RCC) Using Carevive Software, a Single-Arm Phase II Feasibility Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: University of Rochester · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To determine if Carevive software, which monitors treatment-related toxicities and then generates self-care management plans for these symptoms, will be feasible to implement among patients with metastatic renal cell carcinoma (RCC). Additionally for collection of preliminary data on treatment-related toxicities, quality of life, distress level, and drug adherence.

Conditions

• Advanced Renal Cell Carcinoma

Interventions

Type	Name	Description
OTHER	Carevive software	In this study, Carevive will deliver a link to subjects so that an online survey can be completed. The survey will occur weekly for the first 12 weeks of the study and will be spaced out to every other week thereafter. The questions will mostly focus on side effects from their cancer therapy, as well as a few questions about drug compliance and healthcare utilization. After completion of the survey, the subject will be given a care plan with at home self-management options for drug-related toxicities.

Timeline

• Start date: 2019-07-24
• Primary completion: 2025-02-14
• Completion: 2025-02-14
• First posted: 2017-07-25
• Last updated: 2025-02-28

Locations

1 site across 1 country: United States